The Medical Letter on Drugs and Therapeutics
Anoro Ellipta: An Inhaled Umeclidinium/Vilanterol Combination for COPD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved an inhaled fixed-dose combination of the long-acting anticholinergic umeclidinium (ue mek" li din' ee um) and the long-acting beta2-adrenergic agonist (LABA) vilanterol (Anoro Ellipta – GSK/Theravance) for once-daily maintenance treatment of chronic obstructive pulmonary disease (COPD). Anoro Ellipta is the first product available in the US that combines two long-acting bronchodilators in a single delivery device.

This is the first approved indication for umeclidinium in the US. Vilanterol is also available in combination with the corticosteroid fluticasone furoate (Breo Ellipta) for once-daily maintenance treatment of COPD.1

MAINTENANCE TREATMENT OF COPD — For patients with moderate to severe airflow obstruction and chronic symptoms, regular treatment with an inhaled long-acting bronchodilator (a LABA or ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Anoro Ellipta: An Inhaled Umeclidinium Vilanterol Combination for COPD
Article code: 1440b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian